NCT03907488 2025-12-04
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
The Affiliated People's Hospital of Ningbo University
The Affiliated People's Hospital of Ningbo University
Xiamen Amoytop Biotech Co., Ltd.
ChineseAMS
Sun Yat-sen University